← Leaderboards
Terry L Bowlin
Microbiotix, Inc
$33,687,170
Attributed
$36,927,024
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,927,024 · 17
By mechanism
U01$14,933,794 · 2
R44$13,899,305 · 5
R01$3,721,202 · 1
R43$2,214,884 · 6
R56$897,906 · 1
R33$674,963 · 1
Top collaborators
- Kyeong-Ok Chang5 shared
- William C Groutas5 shared
- Linda J. Saif5 shared
- Saul R Tzipori1 shared
Most similar at Microbiotix, Inc
Same institution · by research overlap
- Norton P Peet$3,225,521
- Michelle M. Butler$16,920,917
- Gloria Komazin-Meredith$293,541
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectInfectionSafetyToxicologyExhibitsPharmaceutical PreparationsDrug KineticsIn VivoSeriesPre-ClinicalIn VitroLeadAnalogInhibitor/AntagonistAnimal ModelOralViralDoseCellsPharmacologyUnited StatesEvaluationPropertyRattus
Grant awards (41)
Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis$674,963
R33 · FY2025 · EY · contact PI
Development of well tolerated novel Inhibitors of drug resistant CMV$298,582
R43 · FY2025 · AI · contact PI
Screening for rAAV transduction enhancers$987,813
R44 · FY2023 · AI · contact PI
Screening for rAAV transduction enhancers$986,692
R44 · FY2022 · AI · contact PI
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis$712,798
R44 · FY2022 · EY · contact PI
Screening for rAAV transduction enhancers$999,976
R44 · FY2021 · AI · contact PI
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis$749,526
R44 · FY2021 · EY · contact PI
Discovery of Zika virus therapeutics using a replicon assay$284,970
R41 · FY2019 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2018 · AI
Discovery of Zika virus therapeutics using a replicon assay$300,000
R41 · FY2018 · AI · contact PI
Screening for rAAV transduction enhancers$290,608
R43 · FY2018 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2017 · AI
Screening for rAAV transduction enhancers$299,999
R43 · FY2017 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2016 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2015 · AI
Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication$289,557
R43 · FY2015 · AI · contact PI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents$1,000,000
R44 · FY2014 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$784,022
R01 · FY2014 · AI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents$990,305
R44 · FY2013 · AI · contact PI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$884,280
U01 · FY2013 · AI · contact PI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,174,338
U01 · FY2012 · AI · contact PI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents$1,000,000
R44 · FY2012 · AI · contact PI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,334,916
U01 · FY2011 · AI · contact PI
Evaluation of a new class of antimicrobial agents against Clostridium difficile$897,906
R56 · FY2011 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,909,652
U01 · FY2010 · AI · contact PI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,124,408
U01 · FY2010 · AI · contact PI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents$313,028
R43 · FY2010 · AI · contact PI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$2,219,077
U01 · FY2009 · AI · contact PI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,149,999
U01 · FY2009 · AI · contact PI
A Potent Oral Therapy for Cytomegalovirus Infection$1,076,294
R44 · FY2009 · AI · contact PI
Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents$320,545
R43 · FY2009 · AI · contact PI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,611,536
U01 · FY2008 · AI · contact PI
A Potent Oral Therapy for Cytomegalovirus Infection$1,124,230
R44 · FY2008 · AI · contact PI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,594,896
U01 · FY2007 · AI · contact PI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,930,692
U01 · FY2006 · AI · contact PI
A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION$1,428,397
R44 · FY2006 · AI · contact PI
A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION$1,367,168
R44 · FY2005 · AI
NMSO3: A NOVEL THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS$711,375
R44 · FY2005 · AI
NMSO3: A NOVEL THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS$764,731
R44 · FY2004 · AI
A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION$303,697
R43 · FY2003 · AI
Glucosidase inhibitors as anti-influenza agents$98,868
R43 · FY2001 · AI